Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

Spyre Therapeutics announced the appointment of Kate Chevlen as Chief Commercial Officer, granting her 108,155 stock options at an exercise price of $34.09 per share as an inducement award. The options vest over four years with a 10-year term.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares for approximately $460,000 on January 2, 2026, representing 2.2% of his direct holdings. The sale was conducted under a prearranged 10b5-1 trading plan, which is a standard practice for insiders to avoid appearance of impropriety. After the transaction, Turtle retained approximately 671,907 shares valued at $20.5 million. The analyst notes the sale is not concerning given the scheduled nature of the plan.

Spyre Therapeutics presented scientific data on SPY072, a potential first-in-class anti-TL1A agent for rheumatic diseases, showcasing promising Phase 1 study results with potential quarterly or twice-yearly dosing and preclinical efficacy comparable to etanercept.

Spyre Therapeutics plans to raise approximately $275 million through a public offering of 14,864,865 common stock shares at $18.50 per share, with potential additional shares through underwriter options.

Spyre Therapeutics presented interim Phase 1 results for SPY002, an anti-TL1A antibody for IBD, showing promising dosing potential and preclinical data supporting combination therapy efficacy.

Spyre Therapeutics granted stock options to five non-executive employees under its 2018 Equity Inducement Plan, with options vesting over four years and an exercise price of $16.26 per share.

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) rose during Tuesday’s session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter. Analysts, on average, estimated revenue of $2.29 billion for the quarter. Excluding share-based compensation expenses, the company reported an adjusted loss of (2.81) yuan or ($0.39) compared to (3.07) yuan in the year-ago quarter and (2.28) yuan in the third quarter of 2023. Analysts had called for a loss of $(0.51) per share. NIO shares gained 3.6% to $5.52 on Tuesday. Here are some other big stocks recording gains in today’s session. Apogee Therapeutics, Inc. (NASDAQ: APGE) shares gained 41.6% to $59.10 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results. Dave ...

Spyre Therapeutics (SYRE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

After losing some value lately, a hammer chart pattern has been formed for Spyre Therapeutics (SYRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.